EU vaccine rollout suffers another blow as CureVac's efficacy fails to clear minimum threshold of 50%

(Natural News) Germany’s CureVac coronavirus (COVID-19) vaccine has been found to be only 47 percent effective against the SARS-CoV-2, the virus behind the pandemic, dropping the company’s shares in Frankfurt and New York by more than 50 percent and erasing more than £5 billion ($6.9 billion) from its market value. The interim results from the...